太阳花
Lv5
1310 积分
2021-07-24 加入
-
Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial
2天前
已完结
-
[Diffuse large B-cell lymphoma complicated with pancreatic fistula and peritonitis following initial chemotherapy]
4天前
求助中
-
[Diffuse large B-cell lymphoma complicated with pancreatic fistula and peritonitis following initial chemotherapy]
4天前
求助中
-
A Phase 1 Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults With Advanced Cancers or Lymphoma
8天前
已完结
-
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
8天前
已完结
-
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
8天前
已完结
-
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study
8天前
已完结
-
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
10天前
已完结
-
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103
10天前
已完结
-
Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
10天前
已完结